Mass spectrum analysis of serum biomarker proteins from patients with schizophrenia

Biomedical Chromatography

Volumn 28, Issue 5, 2014, Pages 654-659

  Zhou, Na ^a   Wang, Jie ^b   Yu, Yaqin ^a   Shi, Jieping ^a   Li, Xiaokun ^a   Xu, Bin ^b   Yu, Qiong ^a  

^a JILIN UNIVERSITY   (China)

^b NATIONAL CENTER OF BIOMEDICAL ANALYSIS   (China)

Author keywords

Marker proteins; Mass spectrometry; Schizophrenia; Serum

Indexed keywords

BIOMARKERS; BODY FLUIDS; DESORPTION; DIAGNOSIS; DISEASES; PEPTIDES; SPECTRUM ANALYSIS;

FIRST EPISODES; HEALTHY CONTROLS; MAGNETIC BEADS; MALDI-TOF-TOF-MS; MARKER PROTEINS; PROTEIN SPECTRA; SCHIZOPHRENIA; SEPARATION SYSTEMS; SERUM; SERUM PROTEINS;

MASS SPECTROMETRY;

BIOLOGICAL MARKER; PLASMA PROTEIN; FIBRINOPEPTIDE A;

ADULT; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; MAGNETIC BEAD SEPARATION; MAGNETIC SEPARATION; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETER; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR DIAGNOSIS; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; BLOOD; CASE CONTROL STUDY; DIAGNOSTIC USE; MASS SPECTROMETRY; MIDDLE AGED; YOUNG ADULT;

ADULT; BIOLOGICAL MARKERS; BLOOD PROTEINS; CASE-CONTROL STUDIES; FEMALE; FIBRINOPEPTIDE A; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84898606532     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.3084     Document Type: Article

References (15)

1. Agranoff D, Fernandez-Reyes D, Papadopoulos MC, Rojas SA, Herbster M, Loosemore A, Tarelli E, Sheldon J, Schwenk A, Pollok R, Rayner CF and Krishna S. Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum. Lancet 2006; 368: 1012-1021.
2. Cheng AJ, Chen LC, Chien KY, Chen YJ, Chang JT, Wang HM, Liao CT and Chen IH. Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology. Clinical Chemistry 2005; 51: 2236-2244.
3. Coelho FM, Reis HJ, Nicolato R, Romano-Silva MA, Teixeira MM, Bauer ME and Teixeira AL. Increased serum levels of inflammatory markers in chronic institutionalized patients with schizophrenia. Neuroimmunomodulation 2008; 15: 140-144.
4. Craddock RM, Huang JT, Jackson E, Harris N, Torrey EF, Herberth M and Bahn S. Increased alpha-defensins as a blood marker for schizophrenia susceptibility. Molecular and Cellular Proteomics 2008; 7: 1204-1213.
5. Dekker LJ, Boogerd W, Stockhammer G, Dalebout JC, Siccama I, Zheng P, Bonfrer JM, Verschuuren JJ, Jenster G, Verbeek MM, Luider TM and Smitt PA. MALDI-TOF mass spectrometry analysis of cerebrospinal fluid tryptic peptide profiles to diagnose leptomeningeal metastases in patients with breast cancer. Molecular and Cellular Proteomics 2005; 4: 1341-1349.
6. Dietrich-Muszalska A and Olas B. The changes of aggregability of blood platelets in schizophrenia. World Journal of Biological Psychiatry 2009; 10: 171-176.
7. Holmes E, Tsang TM, Huang JT, Leweke FM, Koethe D, Gerth CW, Nolden BM, Gross S, Schreiber D, Nicholson JK and Bahn S. Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PloS Medicine 2006; 3: e327.
8. Hu S, Loo JA and Wong DT. Human body fluid proteome analysis. Proteomics 2006; 6: 6326-6353.
9. Huang JT, Leweke FM, Oxley D, Wang L, Harris N, Koethe D, Gerth CW, Nolden BM, Gross S, Schreiber D, Reed B and Bahn S. Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis. PloS Medicine 2006; 3: e428.
10. Huang Z, Shi Y, Cai B, Wang L, Wu Y, Ying B, Qin L, Hu C and Li Y. MALDI-TOF MS combined with magnetic beads for detecting serum protein biomarkers and establishment of boosting decision tree model for diagnosis of systemic lupus erythematosus. Rheumatology (Oxford) 2009; 48: 626-631.
11. Lakhan SE. Schizophrenia proteomics: biomarkers on the path to laboratory medicine? Diagnostic Pathology 2006; 1: 11.
12. Liang T, Wang N, Li W, Li A, Wang J, Cui, J, Liu N, Li Y, Li L, Yang G, Du Z, Li D, He K and Wang G. Identification of complement C3f-desArg and its derivative for acute leukemia diagnosis and minimal residual disease assessment. Proteomics 2010a; 10: 90-98.
13. Liang TT, Wang N, Wang GJ, Li AL, He K, Wang J, Cui JG, Li Y and Li W. Magnetic beads-based biological mass spectrometry technology for evaluating therapeutic efficacy of acute leukemia. Chinese Journal of Analytical Chemistry 2010b; 38: 233-236.
14. Sunderland T, Gur RE and Arnold SE. The use of biomarkers in the elderly: current and future challenges. Biological Psychiatry 2005; 58: 272-276.
15. Villanueva J, Lawlor K, Toledo-Crow R and Tempst P. Automated serum peptide profiling. Nature Protocols 2006; 1: 880-891.